4.5 Article

Identification and characterization of a new G-quadruplex forming region within the kRAS promoter as a transcriptional regulator

期刊

出版社

ELSEVIER
DOI: 10.1016/j.bbagrm.2015.11.004

关键词

G-quadruplex; kRAS; Transcriptional control; Cancer therapeutics

资金

  1. U.S. Department of Defense PRCRP grant [CA130229]
  2. University of Mississippi

向作者/读者索取更多资源

kRAS is one of the most prevalent oncogenic aberrations. It is either upregulated or mutationally activated in a multitude of cancers, including pancreatic, lung, and colon cancers. While a significant effort has been made to develop drugs that target kRAS, their clinical activity has been disappointing due to a variety of mechanistic hurdles. The presented works describe a novel mechanism and molecular target to downregulate kRAS expression-a previously undescribed G-quadruplex (G4) secondary structure within the proximal promoter acting as a transcriptional silencer. There are three distinct guanine-rich regions within the core kRAS promoter, including a previously examined region (G4(near)). Of these regions, the most distal region does not form an inducible and stable structure, whereas the two more proximal regions (termed near and mid) do form strong G4s. G4(near) is predominantly a tri-stacked structure with a discontinuous guanine run incorporated; G4(mid) consists of seven distinct runs of continuous guanines and forms numerous competing isoforms, including a stable three-tetrad stacked mixed parallel and antiparallel loop structures with longer loops of up to 10 nucleotides. Comprehensive analysis of the regulation of transcription by higher order structures has revealed that the guanine-rich region in the middle of the core promoter, termed G4(mid), is a stronger repressor of promoter activity than G4(near). Using the extensive guanine-rich region of the kRAS core promoter, and particularly the G4(mid) structure, as the primary target, future drug discovery programs will have potential to develop a potent, specifically targeted small molecule to be used in the treatment of pancreatic, ovarian, lung, and colon cancers. (C) 2015 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据